Kristina Humphries, MD
Endocrinology, Diabetes & Metabolism · Lexington, KYNPI 1841299369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KY, where the typical reported total is $3,450.
Across 121 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$597
- Abbott$368
- Bayer$200
- Novo Nordisk$146
- AstraZeneca$144
- Boehringer Ingelheim$139
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,73699%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 15 | $597 |
| Abbott | 16 | $368 |
| Bayer | 4 | $200 |
| Novo Nordisk | 9 | $146 |
| AstraZeneca | 10 | $144 |
| Boehringer Ingelheim | 10 | $139 |
| Ascendis Pharma Endocrinology Inc | 1 | $106 |
| Insulet Corporation | 5 | $106 |
| Tandem Diabetes Care, Inc. | 2 | $102 |
| Mannkind Corporation | 6 | $99 |
| Lilly USA, LLC | 6 | $96 |
| Amgen(2 entities) | 5 | $78 |
| Corcept Therapeutics | 4 | $65 |
| Antares Pharma, Inc. | 3 | $59 |
| Medtronic | 2 | $46 |
| Halozyme Inc | 2 | $46 |
| Radius Health, Inc. | 3 | $46 |
| BETA Bionics, Inc. | 1 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Amryt Pharma Holdings Ltd | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Abiomed | 1 | $20 |
| Tolmar, Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$150
- FreeStyle Libre Pro$117
- Yorvipath$106
How this compares
$2,763 in reported general payments places this provider in the 35th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 197 | $231,354 |
| MounjaroTirzepatide | 160 | $223,346 |
| RybelsusSemaglutide | 59 | $104,409 |
| TrulicityDulaglutide | 64 | $102,709 |
| JardianceEmpagliflozin | 85 | $93,928 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $56,204 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $46,190 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $39,281 |
| Repatha SureclickEvolocumab | 61 | $37,913 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $33,376 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $29,819 |
| FarxigaDapagliflozin Propanediol | 20 | $28,936 |
| SynthroidLevothyroxine Sodium | 315 | $27,477 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $22,509 |
| Novolog FlexpenInsulin Aspart | 52 | $21,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $96 | $340,786297 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $146 | $340,406278 claims |
| Boehringer IngelheimJardiance | $139 | $93,92885 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $25 | $42,56856 claims |
| AstraZenecaFarxiga | $144 | $28,93620 claims |
| PfizerEliquis | $12 | $14,50011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Lexington
- Lyle MyersLexington$60K
- Wendell MiersLexington$38K
- Leera PatelLexington$34K
- Simon FisherLexington$26K
- Anna MarinoLexington$23K
- Gordon GuthrieLexington$14K
- Kenneth AinLexington$5K
- Megan MinchLexington$4K
- Walaa AyoubLexington$3K
- Dennis KarounosLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.